Apr 10, 2006
Hi doctor,you once stated for a question's answer "we were all disappointed when two recent promising candidates for new entry inhibitors were dropped from clinical development - one for liver toxicity and the other for lack of clinical efficacy. A third candidate remains in clinical trials, and other new drugs and targets are also in early development."were you talking about gilead and pfizer's entry inhibitor s aplaviroc and maraviroc while the one still in trial is boehringer's vicriviroc? thanks!
Response from Dr. Sherer
I appreciate the chance to clarify that remark. Here's the current status of these three drugs: Aplaviroc has been withdrawn from further development due to liver toxicity; Vicrivoroc had one treatment trial suspended due to clinical underperformance, though other trials with this agent are still underway; and maraviroc trials remain open.
geno test results
- What's The Difference Between Mouth Herpes And Mouth Blisters?
- What Percentage Of Women In The Us Have Bacterial Vaginosis?
- What Is The Best Over The Counter Medicine For Chlamydia?
- What Does Herpes Look Like For A Male?
- What Causes A Recurrence Of Genital Warts?
- Syphilis Prevention And Control
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.